Search

Displaying results 931 - 940 of 4600 in total
  1. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.

  2. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    The administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittentl...

  3. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879]

  4. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  5. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions. … Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).

  6. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid

  7. Drug

    Caffeine

    go.drugbank.com/drugs/DB00201
    ApprovedInvestigational

    [A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. … [T716] Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

    Mixtures: Up and Up Migraine Relief, IBUFLASH UF®International brands: Wake-Up
  8. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    , and are switched to camizestrant while continuing the same CDK4/6 inhibitor. … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing

  9. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.

  10. Drug

    Phenazopyridine

    go.drugbank.com/drugs/DB01438
    ApprovedInvestigational

    In the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]